NSABP BP-59

Terminated

Return to Protocol Table

Bone Marrow Analysis in Early-Stage Breast Cancer

Principal Investigator

David Krag

Status

Terminated

Date Opened To Accrual

January 29, 2007

Date Closed To Accrual

April 20, 2011

Date of Study Termination

August 13, 2018


Disease Site

Breast [BR] Breast

Phase

III

Developmental Therapeutics

No

Primary Objective

The primary aim is to determine the relative risk of death associated with the presence of tumor cells in the bone marrow of patients with early-stage breast cancer.

The primary endpoint for analysis is overall survival (OS), where OS will be the time from entry into the study to death from any cause.

Patient Population

Patients with early-stage breast cancer who were to undergo breast surgery were eligible for participation.

Protocol Record Retention Dates
Date Records No Longer to be Kept by US Sites: 08/13/2021
Date Records No Longer to be kept by Canadian Sites: 08/13/2033

Target Accrual

1634

Patient Study Webpage

There is no available patient study webpage available for this trial at this time.